The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Wistar Institute receives $10M donation

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The Wistar Institute received a $10 million donation from an anonymous donor who previously committed $20 million to support Wistar’s new Center for Advanced Therapeutics. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Cancer Policy

Trump administration and Cornell reach agreement to restore federal research funding

Cornell University has come to an agreement with the Trump administration that will unfreeze the university’s more than $250 million in interrupted federal research funding and “protect Cornell’s students from violations of federal civil rights laws, including from discrimination based on race, sex, or national origin, and promote America’s hardworking farming and rural communities” following accusations of antisemitism and discrimination in admissions.
By Jacquelyn Cobb and Claire Marie Porter
Drugs & Targets

EC approves Keytruda combination for a head-and-neck indication

The European Commission approved Keytruda (pembrolizumab), an anti-PD-1 therapy, as a monotherapy for the treatment of resectable locally advanced head-and-neck squamous cell carcinoma as neoadjuvant treatment, continued as adjuvant treatment in combination with radiation therapy with or without concomitant cisplatin and then as monotherapy in adults whose tumors express PD-L1 with a Combined Positive Score ≥1. 
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account